Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin
90-day dosing study is a prerequisite to Phase 3 confirmatory studies under FDA’s BLA NEW YORK, April 23, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun screening patients in its 90-day dose-ranging Pivotal Phase 2b […]
